2026 Congenital ichthyosiform erythroderma indication strategy covering epidemiology, ALOX12B biology, active trials, transactions, unmet need, competition and…

2026 Peeling skin syndrome indication strategy covering epidemiology, CDSN biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Recessive dystrophic epidermolysis bullosa indication strategy covering epidemiology, COL7A1 biology, active trials, transactions, unmet need, competition…

2026 Harlequin ichthyosis indication strategy covering epidemiology, ABCA12 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Porokeratosis indication strategy covering epidemiology, MVK biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Transient acantholytic dermatosis indication strategy covering epidemiology, ATP2A2 biology, active trials, transactions, unmet need, competition and market…

2026 Very early onset inflammatory bowel disease indication strategy covering epidemiology, IL-10 biology, active trials, transactions, unmet need, competition…

2026 Kindler epidermolysis bullosa indication strategy covering epidemiology, FERMT1 biology, active trials, transactions, unmet need, competition and market…

2026 Epidermolysis bullosa simplex indication strategy covering epidemiology, KRT14 biology, active trials, transactions, unmet need, competition and market…

2026 Chronic granulomatous disease-associated colitis indication strategy covering epidemiology, NADPH oxidase biology, active trials, transactions, unmet need,…

2026 IPEX-associated enteropathy indication strategy covering epidemiology, FOXP3 biology, active trials, transactions, unmet need, competition and market…

2026 Trichohepatoenteric syndrome indication strategy covering epidemiology, TTC37 biology, active trials, transactions, unmet need, competition and market…